

Keep up with the latest information from *Diabetes* and other ADA titles via Facebook ([/DiabetesJournals](#)) and Twitter ([@ADA\\_Journals](#)).

## PERSPECTIVES IN DIABETES

Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?

J. LIU, T. LEE, AND R.A. DEFONZO 2199

Human β-cell proliferation and intracellular signaling: driving in the dark without a road map

R.N. KULKARNI, E.-B. MIZRACHI, A.G. OCANA, AND A.F. STEWART 2205

## COMMENTARIES

Immunotherapy in type 1 diabetes: a shorter but more winding road?

E. BONIFACIO 2214

Energizing the mind and body

P. KIEVIT AND J.Q. PURNELL 2216

Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?

C.F. DEACON 2219

The artificial pancreas

J. RADZIUK 2221

Endothelial insulin and IGF-1 receptors: when yes means no

R. MUNIYAPPA AND J.R. SOWERS 2225

Loss of pulsatile insulin secretion: a factor in the pathogenesis of type 2 diabetes?

J. WAHREN AND Á. KALLAS 2228

## METHODOLOGY REVIEW

Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia

M. BRETON, A. FARRET, D. BRUTTOMESSO, S. ANDERSON, L. MAGNI, S. PATEK, C. DALLA MAN, J. PLACE, S. DEMARTINI, S. DEL FAVERO, C. TOFFANIN, C. HUGHES-KARVETSKI, E. DASSAU, H. ZISSE, F.J. DOYLE, G. DE NICOLAO, A. AVOGARO, C. COBELLI, E. RENARD, AND B. KOVATCHEV, ON BEHALF OF THE INTERNATIONAL ARTIFICIAL PANCREAS (IAP) STUDY GROUP 2230

## METABOLISM

Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients

A. BERTOLA, T. CIUCCI, D. ROUSSEAU, V. BOURLIER, C. DUFFAUT, S. BONNAFOUS, C. BLIN-WAKKACH, R. ANTY, A. IANNELLI, J. GUGENHEIM, A. TRAN, A. BOULOUMIÉ, P. GUAL, AND A. WAKKACH 2238

Insulin-like growth factor axis and risk of type 2 diabetes in women

S.N. RAJPATHAK, M. HE, Q. SUN, R.C. KAPLAN, R. MUZUMDAR, T.E. ROHAN, M.J. GUNTER, M. POLLAK, M. KIM, J.E. PESSION, J. BEASLEY, J. WYLIE-ROSETT, F.B. HU, AND H.D. STRICKLER 2248

Famine exposure in the young and the risk of type 2 diabetes in adulthood

A.F.M. VAN ABELEEN, S.G. ELIAS, P.M.M. BOSSUYT, D.E. GROBBEE, Y.T. VAN DER SCHOUW, T.J. ROSEBOOM, AND C.S.P.M. UITERWAAL 2255

Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans

K. JAUCH-CHARA, A. FRIEDRICH, M. REZMER, U.H. MELCHERT, H.G. SCHOLAND-ENGLER, M. HALLSCHMID, AND K.M. OLTMANNS 2261

Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling

A.V. MATVEYENKO, D. LIUWANTARA, T. GURLO, D. KIRAKOSSIAN, C. DALLA MAN, C. COBELL, M.F. WHITE, K.D. COPPS, E. VOLPI, S. FUJITA, AND P.C. BUTLER 2269

## SIGNAL TRANSDUCTION

Hyperglycemia causes renal cell damage via CCN2-induced activation of the TrkA receptor: implications for diabetic nephropathy

M. FRAGIADAKI, N. HILL, R. HEWITT, G. BOU-GHARIOS, T. COOK, F.W. TAM, J. DOMIN, AND R.M. MASON 2280

Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine

S. USSAR, O. BEZY, M. BLÜHER, AND C.R. KAHN 2289

## OBESITY STUDIES

Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium

D.-H. KIM, M.A. SARTOR, J.R. BAIN, D. SANDOVAL, R.D. STEVENS, M. MEDVEDOVIC, C.B. NEWGARD, S.C. WOODS, AND R.J. SEELEY 2299

Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice

I. MOTHE-SATNEY, C. FILLOUX, H. AMGHAR, C. PONS, V. BOURLIER, J. GALITZKY, P.A. GRIMALDI, C.C. FÉRAL, A. BOULOUMIÉ, E. VAN OBBERGHEN, AND J.G. NEELS 2311

An inhibitor of phospholipase A<sub>2</sub> group II A modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats

A. IYER, J. LIM, H. POUDYAL, R.C. REID, J.Y. SUEN, J. WEBSTER, J.B. PRINS, J.P. WHITEHEAD, D.P. FAIRIE, AND L. BROWN 2320

Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c<sup>+</sup> cells in adipose tissue and liver

M. STEFANOVIĆ-RACIC, X. YANG, M.S. TURNER, B.S. MANTELL, D.B. STOLZ, T.L. SUMPTER, L.J. SIPULA, N. DEDOUSIS, D.K. SCOTT, P.A. MOREL, A.W. THOMSON, AND R.M. O'DOHERTY 2330

## IMMUNOLOGY AND TRANSPLANTATION

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

S.A. LONG, M. RIECK, S. SANDA, J.B. BOLLYKY, P.L. SAMUELS, R. GOLAND, A. AHMANN, A. RABINOVITCH, S. AGGARWAL, D. PHIPPARD, L.A. TURKA, M.R. EHRLERS, P.J. BIANCHINE, K.D. BOYLE, S.A. ADAH, J.A. BLUESTONE, J.H. BUCKNER, AND C.J. GREENBAUM, FOR DIABETES TRIALNET AND THE IMMUNE TOLERANCE NETWORK 2340

## PATHOPHYSIOLOGY

The role of endogenous incretin secretion as amplifier of glucose-stimulated insulin secretion in healthy subjects and patients with type 2 diabetes

H.J. WOERLE, L. CARNEIRO, A. DERANI, B. GÖKE, AND J. SCHIRRA 2349

Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice

H. IMRIE, H. VISWAMBHARAN, P. SUKUMAR, A. ABBAS, R.M. CUBBON, N. YULDASHEVA, M. GAGE, J. SMITH, S. GALLOWAY, A. SKROMNA, S.T. RASHID, T.S. FUTERS, S. XUAN, V.K. GATENBY, P.J. GRANT, K.M. CHANNON, D.J. BEECH, S.B. WHEATCROFT, AND M.T. KEARNEY 2359

## COMPLICATIONS

Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study

A. GAMBINERI, L. PATTON, P. ALTIERI, U. PAGOTTO, C. PIZZI, L. MANZOLI, AND R. PASQUALI 2369

Resting-state brain functional connectivity is altered in type 2 diabetes

G. MUSEN, A.M. JACOBSON, N.R. BOLO, D.C. SIMONSON, M.E. SHENTON, R.L. MCCARTNEY, V.L. FLORES, AND W.S. HOOGENBOOM 2375

## PHARMACOLOGY AND THERAPEUTICS

Postprandial platelet activation is related to postprandial plasma insulin rather than glucose in patients with type 2 diabetes

G. SPECTRE, C.-G. ÖSTENSON, N. LI, AND P. HJEMDAHL 2380

## GENETICS/GENOMES/PROTEOMICS/METABOLOMICS

The Gly(972)Arg variant of human IRS1 gene is associated with variation in glomerular filtration rate likely through impaired insulin receptor signaling

F. THAMEEM, S. PUPPALA, J. SCHNEIDER, B. BHANDARI, R. ARYA, N.H. ARAR, T.L. VASYLYEVA, V.S. FAROOK, S. FOWLER, L. ALMASY, J. BLANGERO, R. DUGGIRALA, AND H.E. ABBoud 2385

**ISSUES AND EVENTS****2394****DIABETES DIGESTS****2395****ONLINE LETTERS TO THE EDITOR**

Comment on: Gögebakan et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. *Diabetes* 2012;61:292–300

F.K. KNOP AND M. CHRISTENSEN

e12

Comment on: Turban et al. Optimal elevation of  $\beta$ -cell 11 $\beta$ -hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced  $\beta$ -cell failure. *Diabetes* 2012;61:642–652

J.-L. LIU, C.B. SRIKANT, AND S. CHOWDHURY

e13

Response to comment on: Turban et al. Optimal elevation of  $\beta$ -cell 11 $\beta$ -hydroxysteroid dehydrogenase type 1 is a compensatory mechanism that prevents high-fat diet-induced  $\beta$ -cell failure. *Diabetes* 2012;61:642–652

S. TURBAN, J.R. SECKL, AND N.M. MORTON

e14

Response to comment on: Marquez et al. Low-frequency variants in *HMGA1* are not associated with type 2 diabetes risk. *Diabetes* 2012;61:524–530

P. FROGUEL, M. MARQUEZ, AND S. CAUCHI

e15



The American Diabetes Association (ADA) is the nation's leading voluntary health organization supporting diabetes research, information, and advocacy. Its mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. ADA is the leading publisher of comprehensive diabetes information. Its huge library of books and periodicals covers every aspect of diabetes and diabetes care.

**To join ADA:** Call 1-800-806-7801 or visit [www.diabetes.org/membership](http://www.diabetes.org/membership)

**To subscribe to ADA journals:** Call 1-800-DIABETES or go to [www.diabetesjournals.org](http://www.diabetesjournals.org)

**To order ADA books:** Call 1-800-232-6733 or visit <http://store.diabetes.org>

**To access ADA's library of professional resources:** Go to [professional.diabetes.org](http://professional.diabetes.org)

**For more information about diabetes or ADA programs and services:** Call 1-800-DIABETES. E-mail: [AskADA@diabetes.org](mailto:AskADA@diabetes.org) or visit [www.diabetes.org](http://www.diabetes.org)

**To locate an ADA/NCQA Recognized Provider of quality diabetes care in your area:** Visit <http://web.ncqa.org>

**To join the fight to increase funding for diabetes research, end discrimination, and improve insurance coverage:** Call 1-800-DIABETES or visit [www.diabetes.org/advocate](http://www.diabetes.org/advocate)

**To find out how you can get involved with the programs in your community:** Call 1-800-DIABETES or visit [www.diabetes.org/in-my-community](http://www.diabetes.org/in-my-community)

**To find out about important research regarding diabetes:** Go to [www.diabetes.org/news-research](http://www.diabetes.org/news-research)

**To make a donation or memorial contribution:** Call 1-800-DIABETES or visit [www.diabetes.org/donate](http://www.diabetes.org/donate)